The benign prostatic hyperplasia (BPH) treatment market growth will thrive on factors such as the surging geriatric population, growing prevalence of prostate cancer, soaring awareness of prostate cancer and its treatments, rising adoption of minimally invasive procedures, enhancing healthcare infrastructure, and increasing technological advancements in personalized medicine, during the forecast period (2021–2030). According to P&S Intelligence, the benign prostatic hyperplasia (BPH) treatment market revenue will rise from $10 billion in 2020 to $17 billion by 2030.
One of the prominent growth drivers for the market is the soaring geriatric population across the world. According to the World Ageing Population 2020 report, the population of people aged 65 years or above will reach approximately 1.5 billion by 2050. As old people are highly susceptible to diseases such as BPH, market players are undertaking numerous research and development (R&D) activities to treat prostate conditions, particularly in the aging population, thereby fueling the need for additional care.